FDA approves Merck's Keytruda for FIGO 2014 cervical cancer

Bet_Noire Merck ( NYSE: MRK ) said the FDA has approved its oncology drug Keytruda in combination with chemoradiotherapy for the treatment of FIGO 2014 Stage III IVA cervical cancer. The approval is the drug’s third for the treatment of cervical cancer. Keytruda is now approved for 39 indications in the US, according to the company .

Earlier this month, Merck agreed to acquire oncology drug developer Harpoon Therapeutics ( HARP ) for around $680M. More on Merck Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides) Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript) Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls Harpoon Therapeutics could see interest from other parties, Oppenheimer says Merck on track to snap its seven day win streak.